Is Canada Ready to Adopt Maternal Placental Growth Factor Testing to Improve Clinical Outcomes for Women with Suspected Preeclampsia?
Authors:
- 1 July 2017
- journal article
- editorial
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 39 (7) , 580-583
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected PreeclampsiaCirculation, 2012
- Transcriptionally Active Syncytial Aggregates in the Maternal Circulation May Contribute to Circulating Soluble Fms-Like Tyrosine Kinase 1 in PreeclampsiaHypertension, 2012
- Angiogenic Response of Placental Villi to HeparinObstetrics & Gynecology, 2011
- Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS modelThe Lancet, 2011
- Prevention of Preeclampsia and Intrauterine Growth Restriction With Aspirin Started in Early PregnancyObstetrics & Gynecology, 2010
- Effect of Recombinant Placental Growth Factor 2 on Hypertension Induced by Full-Length Mouse Soluble fms-Like Tyrosine Kinase 1 Adenoviral Vector in Pregnant MiceHypertension, 2009
- Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trialThe Lancet, 2009
- Maternal cardiac function in normotensive and pre‐eclamptic intrauterine growth restrictionUltrasound in Obstetrics & Gynecology, 2008
- Circulating Angiogenic Factors in Early Pregnancy and the Risk of Preeclampsia, Intrauterine Growth Restriction, Spontaneous Preterm Birth, and StillbirthObstetrics & Gynecology, 2007
- Placental Growth Factor and Soluble FMS-Like Tyrosine Kinase-1 in Early-Onset and Late-Onset PreeclampsiaObstetrics & Gynecology, 2007